Quality of Life Claims In Sanctura Journal Advertisement Cited By FDA
Executive Summary
FDA sets a high bar for the type of data needed to substantiate a "quality of life" claim in a letter citing a journal advertisement for Indevus/ Allergan's overactive bladder treatment Sanctura
You may also be interested in...
FDA Enforcement Letters On Rx Drug Promotions Plummet In 2013
OPDP Director Tom Abrams cautions against reading into the “snapshot.”
WellPoint Seeks More Quality Of Life, Cost Data In Formulary Submissions
WellPoint's updated formulary submission guidelines aim to give drug companies more detailed advice on submitting information on a drug's cost-effectiveness and its impact on pharmacy and medical budgets, as well as its effectiveness in improving patients' quality of life
Big Pharma Still Hopeful For Next Mega Drugs To Supplement Sales
Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.